种族差异和HER2蛋白表达对乳腺癌诊断年龄的影响:一种混合方法研究
Martinlina Seranline Karutjaiva1, Yapo Guillaume Aboua1, Beauty Etinosa Omoruyi2
1Department of Health Sciences, Namibia University of Science and Technology, Windhoek, Namibia.
Cancer management and research
|March 11, 2026
概括
纳米比亚土著妇女比美国妇女更年轻时被诊断出患有乳腺癌 (BC). 人体表皮生长因子受体2 (HER2) 蛋白质表达和BC诊断年龄的种族差异凸显了需要量身定制的查方法.
科学领域:
- 在瘤学瘤学.
- 人口遗传学 人口遗传学
- 全球健康 全球健康
背景情况:
- 乳腺癌 (BC) 研究取得了进展,但在理解种族,人体表皮生长因子受体2 (HER2) 蛋白质表达和诊断时的年龄的相互作用方面仍然存在差异,特别是在代表性不足的非洲人群中.
- 关于BC特征和诊断年龄的种族差异存在显著的研究差距,特别是在非洲土著社区中.
研究的目的:
- 分析HER2蛋白表达的变化和BC诊断时的年龄的种族差异在纳米比亚和美国土著妇女中.
- 为了阐明BC诊断年龄和HER2状态在不同种族群体之间的差异.
主要方法:
- 一项混合方法研究分析了来自cBioPortal数据库的1,953名被诊断患有侵入性BC的妇女 (98名纳米比亚土著,1855名美国人) 的病例系列队列.
- 通过乳腺组织活检染色和HER2蛋白表达量的量化对HER2阳性率的回顾性分析.
- 统计分析包括千平方测试,独立性t测试和累积概率分析,p<0.05被认为是显著的.
主要成果:
- 与白人 (p<0.0001) 和非洲裔美国人 (p=0.0035) 妇女相比,纳米比亚土著妇女在较年轻的年龄被诊断出患有BC.
- 与白人女性相比,患有BC的非裔美国女性HER2阳性状态的几率明显较低 (OR = 0.52,p < 0.001).
- 累积概率分析显示,与白人女性相比,纳米比亚,亚洲和非洲裔美国妇女的BC诊断年龄较小的概率显著更高 (p<0.0001,p=0.0035,p=0.0057).
结论:
- 在HER2蛋白表达和BC诊断时的年龄之间,纳米比亚土著和美国妇女之间的种族差异很明显.
- 定制的种群遗传学和地理特定的BC查方法是解决全球BC查公平性的必要.
- 了解这些种族差异对于开发有针对性的干预措施和改善全球BC结果至关重要.
相关概念视频
Cancer Survival Analysis
808
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808
Pharmacodynamics in Geriatric Patients: Effects of Age
307
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
307


